Converge Bio — Startup Profile
Generative AI for drug discovery and development
HQ: Tel Aviv, Israel | Founded: 2024 | Employees: Not publicly disclosed | Stage: Early-stage, venture-backed biotech | Website: https://converge-bio.com
About
Converge Bio develops generative AI tools intended to help biotech and pharmaceutical companies discover drugs faster by modeling biological systems and drug interactions.
The Take
Converge is targeting the expensive translation gap between biological data and therapeutic decisions. The commercial opportunity is broad, but drug-discovery software ultimately has to show validated biological and clinical outcomes, not only compelling model outputs.
Key Metrics
- Founded: 2024
- Founders: Dov Gertz; Oded Kalev; Iddo Weiner
- Latest signal: Converge Bio raises $25M Series A
- Funding rounds cited: 2
Funding Rounds
- Round: $25M (2026-01) — Bessemer Venture Partners
- Round: $5.5M (2024-11) — Not fully disclosed
Key People
- Dov Gertz
- Oded Kalev
- Iddo Weiner
Key Competitors
- Incumbent platforms —
- Specialist startups —
Timeline Highlights
- 2024-11: Seed
- 2026-01: Series A
- 2024: Founded
Recent News
- Converge Bio raises $25M Series A (2026-01-13)
Similar Startups
- Aether Biomachines — Designing industrial proteins with computers and biology.
- Cresta — Enterprise AI platform for contact centers — real-time coaching for human agents plus AI virtual age
- Enveda Biosciences — Finding medicines in the chemistry of nature.
- Chai Discovery — The computer-aided design suite for molecules
- Adept — AI systems that act across software interfaces
Browse: Home | Blog | About | All Startups A-Z | View full profile on StartupWiki